Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

TargetPrior: A miRNA-Signature Embedded Evolutionary Learning Framework for Prioritizing Drug Targets in Acute Myeloid Leukemia.

Created on 27 Aug 2026

Authors

Ting-Yu Chen, Shinn-Ying Ho

Published in

Bioinformatics (Oxford, England). Aug 27, 2026. Epub Aug 27, 2026.

Abstract

Prioritizing therapeutic targets from high-dimensional transcriptomic profiles is hindered by the underdetermined nature of the p ≫  n setting. While miRNA signatures can inform target prioritization, conventional accuracy-driven methods may yield unstable predictive signatures, reducing downstream network reliability and topology-guided candidate ranking.
We propose TargetPrior, a stability-aware evolutionary learning framework in which EL-CAML derives reproducible miRNA anchors from relapse-associated transcriptomic variation for candidate target prioritization. In childhood acute myeloid leukemia (CAML), EL-CAML identifies a parsimonious 18-miRNA continuous relapse-risk signature and 10 complementary stability-supported biomarkers, yielding 28 miRNAs for literature-curated miRNA-gene network construction. Repeated perturbation analysis supported the stability of high-frequency miRNAs, while analysis of the independent GSE196886 cell-sorted small RNA-seq dataset identified cell-population-specific expression differences. Benchmarking against an expanded set of clinically and biologically supported AML target references showed stronger early-rank retrieval than network-only and statistical approaches. TargetPrior is presented as a computational proof-of-concept for generating prioritized therapeutic hypotheses, rather than as a universal target-discovery solution.
Code is available at: https://github.com/NYCU-ICLAB/TargetPrior and archived on Zenodo (DOI: 10.5281/zenodo.20394263).
Supplementary data are available at Bioinformatics online.

PMID:
42658031
Bibliographic data and abstract were imported from PubMed on 27 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement